Pertuzumab (2C4 antibody; R-1273; rhuMAb2C4) is a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). Pertuzumab is the first in a new class of anticancer agents called HER dimerisation inhibitors. Pertuzumab binds to the HER2 receptor and prevents the pairing (dimerisation) of HER2 with other HER family receptors, inhibiting intracellular signalling. Pertuzumab and trastuzumab bind to different regions of HER2 and may potentially provide synergistic activity. In trials, pertuzumab was administered by intravenous (IV) infusion with a loading dose of 840mg followed by 420mg every three weeks in combination with trastuzumab and docetaxel.
Acute lymphoblastic leukaemia (ALL) is a type of cancer affecting white blood cells, which results in overproduction of faulty cells. These cells take over the bone marrow leading to anaemia, infection, bruising and bleeding. ALL is a rare condition, usually affecting more children than adults. Lymphoblastic lymphoma (LBL) is similar to ALL, they differ in where they often occur in the body (lymph nodes and thymus gland in LBL, and blood and bone marrow in ALL), and they are both treated in the same way.